Significance of angiotensin type 1 receptor blockade: why are angiotensin II receptor blockers different? (Q33788382)

29 July 2017

1 reference

title

Significance of angiotensin type 1 receptor blockade: why are angiotensin II receptor blockers different? (English)

1 reference

29 July 2017

T Unger

1

1 reference

29 July 2017

language of work or name

English

0 references

publication date

1 November 1999

1 reference

American Journal of Cardiology

29 July 2017

published in

1 reference

29 July 2017

volume

84

1 reference

29 July 2017

issue

10A

1 reference

29 July 2017

page(s)

9S-15S

1 reference

Renin, angiotensin and aldosterone system in pathogenesis and management of hypertensive vascular disease

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900728-6

Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900728-6

Oral angiotensin-converting-enzyme inhibitors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900728-6

Angiotensin II receptor pharmacology and AT1-receptor blockers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900728-6

The efficacy and safety of valsartan compared with placebo in the treatment of patients with essential hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900728-6

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900728-6

Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy, tolerability and safety compared to an angiotensin-converting enzyme inhibitor, lisinopril

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900728-6

A randomised, double-blind comparison of the angiotensin II receptor antagonist, irbesartan, with the full dose range of enalapril for the treatment of mild-to-moderate hypertension.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900728-6

Comparison of the angiotensin II antagonist losartan with the angiotensin converting enzyme inhibitor enalapril in patients with essential hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900728-6

Angiotensin II receptor antagonists in hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900728-6

Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin II receptor antagonist, in man

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900728-6

Losartan potassium: a review of its pharmacology, clinical efficacy and tolerability in the management of hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900728-6

The antihypertensive effect and tolerability of candesartan cilexetil, a new generation angiotensin II antagonist, in comparison with losartan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900728-6

Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan in mild-to-moderate hypertension. Irbesartan/Losartan Study Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900728-6

Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900728-6

Inhibition of rabbit aortic angiotensin II (AII) receptor by CV-11974, a new nonpeptide AII antagonist

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900728-6

Preclinical pharmacology of angiotensin II receptor antagonists: update and outstanding issues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900728-6

Pharmacological profile of valsartan: a potent, orally active, nonpeptide antagonist of the angiotensin II AT1-receptor subtype

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900728-6

Pharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist, BIBR 277

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900728-6

Pharmacologic properties of candesartan cilexetil--possible mechanisms of long-acting antihypertensive action

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900728-6

Mechanistic differences of various AT1-receptor blockers in isolated vessels of different origin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900728-6

10.1016/S0002-9149(99)00728-6

7 January 2021

Identifiers

DOI

1 reference

29 July 2017

1 reference